首页 News 正文

BeiGene responds to AbbVie's lawsuit alleging theft of trade secrets: with the intention of obstructing the development process

海角七号
184 0 0

Blue Whale News, September 12th (Reporter Tu Jun) Following the patent infringement lawsuit filed by AbbVie in June last year regarding its core product BTK inhibitor Baiyueze (Zebutinib Capsules), it has been reported that pharmaceutical giant AbbVie once again sued BeiGene last Friday. The former sued BeiGene in the Federal Court of Chicago, accusing it of stealing trade secrets to develop competitive anti-cancer therapies after hiring a former senior scientist from AbbVie.
It is reported that the above-mentioned project includes the compound BGB-16673 independently discovered by BeiGene researchers through years of innovative research.
On August 27th, BeiGene announced that the US FDA has granted BGB-16673 fast track eligibility for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously received at least two lines of treatment, including BTK inhibitors and BCL2 inhibitors. BGB-16673 is an orally administered, BTK targeted chimeric degradation activating compound (CDAC) under development.
BeiGene has stated to Blue Whale Finance that it will provide a firm defense against the allegations made by AbbVie. BeiGene denies this accusation and will firmly defend its intellectual property rights against the lawsuit.
We believe that the lawsuit intends to impede the development process of BGB-16673, which is currently the fastest progressing BTK degradation agent in clinical development. BeiGene had already applied for a patent for BGB-16673 several years before AbbVie first applied for a BTK degradation agent patent BeiGene said.
So far, over 300 patients from 15 countries and regions have received treatment in the BGB-16673 global clinical development project.
BeiGene stated that the focus on advancing the BGB-16673 development project will not be interrupted by this lawsuit, and the drug has the potential to become an important treatment option for patients with disease progression and limited choices after using BTK inhibitors.
Affected by the news, BeiGene's A-shares fell 10.61% today (September 12th) to HKD 144.01 per share, while Hong Kong stocks fell 5.44% to HKD 118.3 per share.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    6 小时前
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    前天 19:48
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    前天 20:09
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    30 分钟前
    支持
    反对
    回复
    收藏
海角七号 注册会员
  • 粉丝

    0

  • 关注

    1

  • 主题

    29